Bluejay Diagnostics (NASDAQ:BJDX) Director Douglas Clark Wurth Acquires 12,500 Shares

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Douglas Clark Wurth bought 12,500 shares of the stock in a transaction on Saturday, March 14th. The stock was purchased at an average price of $2.00 per share, for a total transaction of $25,000.00. Following the completion of the purchase, the director owned 12,608 shares of the company’s stock, valued at approximately $25,216. This trade represents a 11,574.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Bluejay Diagnostics Price Performance

Shares of BJDX opened at $1.72 on Tuesday. The firm has a market cap of $1.78 million, a PE ratio of -0.15 and a beta of 0.72. The stock’s fifty day moving average price is $1.90 and its two-hundred day moving average price is $3.19. Bluejay Diagnostics, Inc. has a 1 year low of $1.63 and a 1 year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Institutional investors and hedge funds own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.